Collegium Pharma (COLL) Misses Q3 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
November 12, 2015 6:02 AM ESTCANTON, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the third quarter of 2015 and provided a corporate update.
"During the last few months, Collegium achieved a number of important milestones in moving Xtampza ER closer to market launch upon final approval," stated Michael Heffernan, Collegium's CEO. "We were very encouraged by the FDA Advisory Committees' unanimous vote in support of approval of Xtampza ER and subsequently the FDA's tentative approval of the Xtampza ER NDA. Additionally, the commercial team has made significant progress in preparing for... More
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
November 12, 2015 6:01 AM ESTCANTON, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the third quarter of 2015 and provided a corporate update.
"During the last few months, Collegium achieved a number of important milestones in moving Xtampza ER closer to market launch upon final approval," stated Michael Heffernan, Collegium's CEO. "We were very encouraged by the FDA Advisory Committees' unanimous vote in support of approval of Xtampza ER and subsequently the FDA's tentative approval of the Xtampza ER NDA. Additionally, the commercial team has made significant progress in preparing for... More
